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Abstract Attention-deficit/hyperactivity disorder
(ADHD) is a common childhood onset neuropsychiatric
disorder with a complex and heterogeneous symptomatol-
ogy. Persistence of ADHD symptoms into adulthood is
common. Methylphenidate (MPH) is a widely prescribed
stimulant compound that may be effective against ADHD
symptoms in children and adults. However, MPH does not
exert satisfactory effect in all patients. Several genetic
variants have been proposed to predict either treatment
response or adverse effects of stimulants. We conducted a
literature search to identify previously reported variants
associated with MPH response and additional variants that
were biologically plausible candidates for MPH response.
The response to MPH was assessed by the treating clini-
cians in 564 adult ADHD patients and 20 genetic variants
were successfully genotyped. Logistic regression was used
to test for association between these polymorphisms and
treatment response. Nominal associations (p\ 0.05) were
meta-analysed with published data from previous compa-
rable studies. In our analyses, rs1800544 in the ADRA2A
gene was associated with MPH response at a nominal
significance level (OR 0.560, 95 % CI 0.329–0.953,
p = 0.033). However, this finding was not affirmed in the
meta-analysis. No genetic variants revealed significant
associations after correction for multiple testing
(p\ 0.00125). Our results suggest that none of the studied
variants are strong predictors of MPH response in adult
ADHD as judged by clinician ratings, potentially except for
rs1800544. Consequently, pharmacogenetic testing in
routine clinical care is not supported by our analyses.
Further studies on the pharmacogenetics of adult ADHD
are warranted.
Keywords ADHD  Pharmacogenetics  ADRA2A 
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neu-
ropsychiatric disorder characterized by developmentally
inappropriate levels of impulsivity, hyperactivity and
inattention (American Psychiatric Association 2013). Most
ADHD patients are diagnosed in childhood and the
symptoms are thought to persist into adulthood in its full
syndromic form in approximately 35 % of the patients.
However, more than 70 % of the patients may be burdened
by ADHD symptoms or experience ADHD-related func-
tional impairment as adults (Biederman et al. 2010, 2012).
The first-line pharmacological option in the treatment of
ADHD in children and adults is methylphenidate (MPH)
(National Institute for Health and Clinical Excellence
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2008; Norwegian Directorate of Health 2014). MPH has
been shown superior to placebo in providing symptom
relief in ADHD (Epstein et al. 2014; Faraone and Buitelaar
2010), and is believed to exert its effect by inhibiting the
dopamine transporter (encoded by DAT/SLC6A3 gene) and/
or the noradrenaline transporter (encoded by NET/SLC6A2
gene) (Engert and Pruessner 2008). Although the exact
mechanisms of MPH’s effects remain unknown, the inhi-
bition of these transporters is thought to affect the extra-
cellular concentrations of dopamine and noradrenaline in
the brain, predominantly in the prefrontal cortex and
striatum, and thus, moderate the symptoms of ADHD
(Arnsten and Pliszka 2011; Engert and Pruessner 2008).
The response rates to MPH among adult ADHD patients
range from 25 to 78 % in controlled trials (Wilens et al.
2011). A portion of this variability is likely explained by
the definition of response, diagnostic criteria, sample
characteristics, drop-outs and dosing parameters (Fredrik-
sen et al. 2013; Wilens et al. 2011). In addition, some
patients experience adverse effects that outweigh the
therapeutic impact, although serious adverse effects are
considered rare (Fredriksen et al. 2013). Genetic variations
may contribute to variability in MPH response. Previous
studies have investigated several single nucleotide poly-
morphisms (SNPs) and variable tandem repeats (VNTRs),
mostly in or near genes involved in the dopamine and
noradrenaline systems, as well as in genes encoding MPH
metabolizing enzymes (Bruxel et al. 2014). Still, most
reports have been negative for any association, or the
results have been conflicting (Bruxel et al. 2014; Kambeitz
et al. 2014).
One explanation for the lack of consistent pharmaco-
genetic findings could be the polygenic and multifactorial
nature of ADHD, with genetic variants contributing small
effects to its aetiology and, consequently, requiring large
sample sizes in order to detect such effects. An additional
potentially important factor may be the phenotypic
heterogeneity of ADHD. Moreover, the symptoms of
ADHD tend to change with age with most studies reporting
a more pronounced decline in the hyperactivity and
impulsivity symptoms, as compared to the inattention
symptoms (Biederman et al. 2010, 2012; Pingault et al.
2015). MPH may not be effective against all ADHD
symptoms to the same extent and the effect of MPH may
change over time. Thus, pharmacogenetic studies con-
ducted in ADHD children may not be directly applicable to
adults. Despite this lack of reliable genetic markers in the
published literature and the uncertainties regarding the
impact of aging, several commercial genetic tests are being
marketed to patients, parents and health care providers to
guide pharmacological intervention in ADHD. Examples
of such commercial tests include ‘‘Harmonyx Test for
ADHD’’ (Harmonyx Diagnostics) and ‘‘GeneSight
ADHD’’ (Assurex Health).
Discovering and affirming genetic variants involved in
the response to MPH in ADHD patients could help guide
treatment strategies with respect to symptom control and
adverse effects, thus helping to secure treatment compli-
ance and adherence (Gajria et al. 2014). This may be of
great importance for adult ADHD patients, who often are
burdened with polypharmacy, comorbidity and socioeco-
nomic distress (Halmoy et al. 2009). In addition, identifi-
cation of pharmacogenetic variants could provide greater
insight into the pharmacodynamics of MPH and the biol-
ogy of ADHD. In this study, we therefore, explored MPH
response in an adult ADHD sample in the light of genetic
variants that have previously been associated with changes
in MPH response. We also hypothesized that variants in the
genes formerly linked to psychiatric or pharmacological
phenotypes and which are involved in MPH metabolism or
MPH pharmacodynamics, could potentially affect the
response to MPH in adult ADHD patients.
Patients and methods
Patient recruitment and assessment of MPH
response
Participants were recruited as part of a large study on adult
ADHD risk factors (Halmoy et al. 2009; Johansson et al.
2008). DNA was extracted from blood or saliva samples
collected from clinically diagnosed adult ADHD patients
of Norwegian descent all over Norway. The diagnosis of
ADHD in adults was based on the Diagnostic and Statis-
tical Manual of Mental Disorders IV (DSM-IV) criteria.
The recruitment protocol has previously been described in
detail elsewhere (Halmoy et al. 2009; Johansson et al.
2008).
The patients’ response to MPH was assessed by two
questionnaires that were filled out by the patients’ treating
physicians, mainly psychiatrists (but also some general
practitioners). The questions were designed to reflect
treatment decisions in routine clinical settings.
In Questionnaire 1, the physicians rated the effect of
‘‘Ritalin’’ and/or ‘‘Concerta’’ which represented immediate
release MPH and extended release MPH, respectively (at
the time Questionnaire 1 was made and first utilized,
‘‘Ritalin’’ was the only immediate release formulation and
‘‘Concerta’’ the only extended release formulation of MPH
available in Norway). The treatment response was rated
with the options: ‘‘Very good’’, ‘‘Good’’, ‘‘Has had effect,
but discontinued due to side effects’’ and ‘‘Not sure or
none’’. The first three categories were grouped as MPH
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responders and ‘‘Not sure or none’’ were defined as MPH
non-responders. Patients who had tried both ‘‘Ritalin’’ and
‘‘Concerta’’, had to be rated as ‘‘Not sure or none’’ on both
items to be defined as MPH non-responders. A minority of
the patients (13 %) were scored on a slightly modified
version of the questionnaire, Questionnaire 2, where the
effect of MPH was rated directly and the response option
‘‘Has had effect, but discontinued due to side effects’’ was
omitted. Here, the first two alternatives were used to define
MPH responders and the third non-responders.
The physicians filling out the questionnaires also stated
the patients’ date of birth and the date the questionnaires
were signed. These data were used to calculate the age of
the patients at the time of questionnaire submission.
The original questionnaire (Questionnaire 1) was
developed, and later revised (Questionnaire 2), by the last
author of this study, Jan Haavik, together with co-workers
during the planning of the larger study on ADHD risk
factors (Halmoy et al. 2009; Johansson et al. 2008).
Selection of genetic variants
To identify genetic polymorphisms (SNPs and VNTRs)
previously associated, either experimentally or theoreti-
cally, with MPH response in child or adult ADHD patients,
we conducted a literature search in PubMed, The Phar-
macogenomics Knowledge Base and Google Scholar. In
addition, variants in genes involved in ADHD pathophys-
iology or MPH metabolism and shown to have pharma-
cogenetic effects were included.
Genotyping and its quality control
All SNPs were genotyped at CIGENE facility at the Nor-
wegian University of Life Sciences (A˚s, Norway), with a
Sequenom MassARRAY iPLEX system (Sequenom, San
Diego, CA, USA) as described previously (Johansson et al.
2010). Variants failing genotyping with the Sequenom
MassARRAY iPLEX system, were genotyped as part of a
larger genotyping effort using Illumina HumanExome
BeadChip 12v1_B (Zayats et al. manuscript in prepara-
tion). VNTRs were genotyped by polymerase chain reac-
tion followed by fragment analysis as previously described
(Johansson et al. 2008).
The VNTR alleles were dichotomized based on the lit-
erature: a specific number of repeats was defined as the risk
allele and all others as non-risk. For DRD5, the148 bp-
repeat allele was defined as the risk allele (Tahir et al.
2000), the 10-repeat allele (10R) was defined as the risk
allele for SLC6A3/DAT1 (Kambeitz et al. 2014) and the
7-repeat allele (7R) as the risk allele for DRD4 (Hamarman
et al. 2004).
In the analyses presented, genotyped SNPs passed
quality control criteria of minor allele frequency (MAF)
over 1 %, missingness below 10 % and Hardy–Weinberg
equilibrium test p value above 0.005. SNP genotype
missingness per individual was set to 15 %.
All included VNTRs demonstrated MAF over 1 %,
missingness below 1 % and passed Hardy–Weinberg
equilibrium test p value above 0.005 after dichotomization.
VNTR genotype missingness per individual was set to a
maximum of one out of three variants.
Genetic association between selected genetic
variants and MPH response
Genetic association between chosen genetic variants and
MPH response was tested in the form of binary logistic
regression implemented in R-software. Sex and age were
included as covariates. Both dominant and additive models
were examined. Multiple testing was controlled by Bon-
ferroni method.
Meta-analysis with previous studies
Genetic variants exhibiting signs of association (p\ 0.05)
were further explored in meta-analysis with the previously
published studies. For this step, published data was
screened with regard to comparability, meaning studies on
adult ADHD patients (17 years of age or more) of Euro-
pean ethnicity with MPH response assessed with a binary
outcome and the variants of interest having a similar allele
distribution to our material.
Once publications suitable for meta-analysis were
identified, reported genetic data were re-examined for
association with MPH response together with our data by
means of Fisher’s exact test. Meta-analysis was carried out
using inverse-variance method in a random effects model
directly from the counts data. Between-study heterogeneity
was assessed by I2 measure. Analyses were performed in
R-software, using Metafor 1.9-4 package (Viechtbauer
2010). Multiple testing was controlled by Bonferroni
method.
Results
Selection of genetic variants, genotyping and its
quality control
Overall, 20 genetic variants were selected: 17 SNPs and 3
VNTRs in 11 genes (Supplementary Table 1 describes the
polymorphisms). All were successfully genotyped.
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After quality control, there were 564 unique patients, of
whom 487 were classified as MPH responders and 77 as
MPH non-responders (Table 1). The number of patients for
the different genotyping platforms is presented in Supple-
mentary Table 2.
Genetic association between selected genetic
variants and MPH response
All results of the association analyses are presented in
Supplementary Table 3. In summary, prior to correction
for multiple testing, one nominally significant (p\ 0.05)
finding in the alpha-2-adrenergic receptor 2A gene
(ADRA2A) was noted. Namely, the G allele of rs1800544
(MspI -1291C[G), located in the 5-untranslated region
(50UTR), was associated with MPH non-response in a
dominant model (OR 0.560, 95 % CI 0.329–0.953,
p = 0.033).
No genetic variations were associated with MPH
response after correction for multiple testing
(p\ 0.00125).
Meta-analysis with previous studies
In total, one variant in a dominant genetic model,
rs1800544, was associated with MPH response prior to
Bonferroni correction for multiple testing and included in
the meta-analysis. After screening the previously identified
literature with our criteria, only one study was performed
on adult ADHD patients of European descent with
dichotomous assessment of MPH response (Contini et al.
2011) and, thus, suitable for meta-analysis together with
our data. The threshold of significance was set to
p\ 0.00122.
The meta-analysis showed no significant effect of
rs1800544 on MPH response (OR 0.711, 95 % CI
0.410–1.232, p = 0.251) (Table 2).
Discussion
Knowledge about the pharmacogenetics of MPH response
may increase our insights into the aetiology of ADHD and
improve patient care. We therefore assessed the genetic
background of MPH response in patients with adult
ADHD.
One SNP, rs1800544, in the 50UTR of the ADRA2A gene
revealed nominal association with MPH response in adult
ADHD patients. Located in a transcription factor binding
site, rs1800544 may affect gene expression and, conse-
quently, MPH’s pharmacological effect on the symptoms
of ADHD (Xu and Taylor 2009). ADRA2A encodes an
adrenergic receptor located pre- and post-synaptically in
both the central and peripheral nervous system. It has been
found to be highly expressed in brain areas that have been
associated with ADHD (Arnsten and Pliszka 2011). In
addition, electrophysiological studies have shown that
MPH may affect cortical excitability through ADRA2A,
which might partly explain MPHs effect on the symptoms
of ADHD (Andrews and Lavin 2006). The selective
ADRA2A agonist guanfacine is used in the treatment of
ADHD, consistent with a potential involvement of
ADRA2A in the pathophysiology of the disorder (Arnsten
and Pliszka 2011). It is noteworthy, however, that meta-
analysis of this variant with a comparable Brazilian study
(Contini et al. 2011), revealed no association. This obser-
vation may be explained by a number of reasons: (a) the
sample size of the Brazilian study is only approximately
one-third of ours, (b) possible genetic admixture as the
reported MAF in the Brazilian study is higher than that
reported for the CEU population (Northern and Western
Europeans from Utah, UT, USA) and more comparable to
that of the MXL population (Mexican Ancestry in Los
Angeles, CA, USA) (Abecasis et al. 2012) and (c), the
phenotypic heterogeneity of ADHD. Thus, meta-analysis
with a larger and more homogeneous sample is warranted.
Table 1 Description of the
examined sample of adult
ADHD patients
Questionnaire 1 Questionnaire 2 Total
Demographics
Sex: male/female 247/246 24/47 271/293
Mean age (SD) 34.0 (10.1) 34.9 (9.7) 34.11 (10.0)
MPH effect
Responder (%) 427 (86.6) 60 (84.5) 487 (86.3)
Non-responder (%) 66 (13.4) 11 (15.5) 77 (13.7)
Total 493 71 564
MPH methylphenidate, SD standard deviation
Questionnaire 1: Patients with MPH response rated as ‘‘Very good’’, ‘‘Good’’ or ‘‘Has had effect, but
discontinued due to side effects’’ defined Responders. ‘‘Not sure or none’’ defined Non-responder
Questionnaire 2: Patients with MPH response rated as ‘‘Very good’’ or ‘‘Good’’ defined Responders. ‘‘Not
sure or none’’ defined Non-responders
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Previously, the G allele of rs1800544 has been noted to
be associated with the improvement of MPH response in
children and adolescents (Cheon et al. 2009; da Silva et al.
2008; Polanczyk et al. 2007). However, negative studies
have also been reported in children and adolescents (Kim
et al. 2011; Park et al. 2013) as well as in adults (Contini
et al. 2011). Interestingly, in our study of adult ADHD, the
G allele was associated with MPH non-response. As the
symptomatology of ADHD is thought to change with age
(Biederman et al. 2010, 2012; Faraone et al. 2006; Pingault
et al. 2015), it is difficult to draw firm conclusions
regarding the exact effect of this allele. There may be age-
related changes in human neurobiology, such as alterations
in gene expression patterns (Shingai et al. 2014).
In general, pharmacogenetic findings in paediatric
ADHD samples reveal little to no replication in adults. This
absence of replication may be explained by age-related
changes in ADHD symptomatology, as well as likely
variability in MPH effect itself. It has been reported in
some studies that, compared to inattention, MPH has
greater impact on the symptoms of hyperactivity and
impulsivity in children (Beery et al. 2013). As inattention is
believed to become more pronounced in the adult form of
ADHD, pharmacological effects of MPH on attention may
be more important in this group. Consequently, the genetic
variants mediating the pharmacogenetic effects of MPH
seen in children may not be of the same importance in
adults. Nonetheless, randomised controlled studies in
adults indicate that MPH is as effective on inattention
symptoms as it is on hyperactivity and impulsivity (Epstein
et al. 2014; Spencer et al. 2005).
Pharmacogenetic testing is being introduced for a
number of neuropsychiatric disorders, including ADHD
(Assurex Health; Dediemar 2015; Harmonyx Diagnostics;
Hicks et al. 2015). Based on our results, such testing in
adult ADHD for any of the variants assessed in our study is
not justified, as only a single variant was nominally asso-
ciated with MPH response. Additionally this effect was in
the opposite direction of what has previously been descri-
bed in studies conducted in children and adolescents.
This study should be viewed in the light of its limita-
tions. Even with 564 participants, which to our knowledge
is the largest pharmacogenetic study in ADHD, our study is
still small and relatively underpowered to detect the small
effect sizes of common variants.
Another limitation of our study may be phenotypic
heterogeneity. Since psychiatric comorbidities, including
substance abuse as well as polypharmacy, are common
among our recruited adult ADHD patients (Halmoy et al.
2009), the MPH response observed in this study is likely to
be affected by these factors (Retz and Retz-Junginger
2014). However, the presence of comorbidities may better
approximate the average ADHD patient encountered in
routine clinical practice (Sobanski et al. 2007). Further-
more, a recent naturalistic survey on instant release MPH
concluded that psychiatric comorbidities may not be
important predictors of medication response (Victor et al.
2014).
The overall treatment response was assessed by clini-
cians using two slightly different variants of a question-
naire. It is unlikely that there were systematic differences
in how the physicians filled out the questionnaires, as the
percentage of treatment responders was very similar in
both (Table 1). Moreover, since this is an observational
study, observer-expectancy effects might be present. The
response rating schemes used in this study were designed
to mirror routine clinical judgement, which is usually based
on symptom scores and additional information provided by
the patients. Thus, such clinical ratings are not directly
comparable to the response scores derived from single
symptom measurements or neuropsychological tests. In
addition, laboratory recorded phenotypes and symptom
rating scales may only capture minor phenotype changes
and core symptom reduction (Beery et al. 2013). In con-
trast, our phenotype may better reflect changes in the
patients’ everyday function.









OR (95 %CI) Crude
p value*
I2
Contini et al. (0.33) GG?GC 67 13 1.069 (0.398–2.824) 1.000
CC 53 11
This study (0.27) GG?GC 194 39 0.587 (0.333–1.024) 0.048
CC 229 27
Meta-analysis 0.711 (0.410–1.232) 0.251 24.17 %
OR[1 means that the variant is associated with MPH response and OR\1 that the variant is associated with MPH non-response
MPH methylphenidate, OR odds ratio, 95 % CI 95 % confidence interval, I2 heterogeneity measure
* Threshold for significance after 40 ? 1 tests p = 0.00122
a In both MPH responders and MPH non-responders
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A substantial proportion of our sample was recruited
through a registry of adult ADHD patients who applied for
stimulant treatment (Johansson et al. 2008). Therefore,
some recruitment bias could be present in our sample. It
may be that our patients had more severe ADHD symptoms
as compared to the ‘‘average’’ ADHD patients, and severity
has been shown to be a positive predictor of MPH response
(Buitelaar et al. 2011; Victor et al. 2014). However, the
patients with the greatest symptom burden are also the
most functionally impaired, and would therefore perhaps
be the ones that could benefit the most from accurate
genetic guidance of pharmacological therapy.
Finally, the strength of the association signals presented
in the previous pharmacogenetic studies also affect the
outcomes of this study. For instance, as several of the
previously reported variants have only been tested in small
and underpowered studies, false positive findings are
likely. Moreover, some of the variants investigated in this
study were tested for association with clinical response to
MPH for the first time.
In summary, none of the examined variants reached the
threshold for statistical significance after correction for mul-
tiple testing. The SNP rs1800544 in ADRA2A, revealed
nominally significant association, but the direction of effect
was the opposite to that reported in previous studies conducted
in children and adolescents. As some of the examined variants
represent the existing pharmacogenetic markers ofMPH, also
used in commercial tests, our results suggest that such tests
cannot reliably predict treatment response in adult ADHD
patients. Therefore, more research is warranted before these
markers can be recommended for routine clinical use.
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